FDA approves KALYDECO (ivacaftor) for use in eight additional mutations that cause cystic fibrosis

24-02-2014 Business Wire HealthComments (0)

KalydecoPharmaceutical

US Food and Drug Administration Approves KALYDECO (ivacaftor) for use in eight additional mutations that cause cystic fibrosis

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top